Smith Giri is an Oncology physician affiliated with Alabama Department of Public Health. OpenAlex indexes 425 publications with 5,449 citations (h-index 36); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2145 Bonner Way
Birmingham, AL 352432949
Telephone
205-978-0250Registry record last updated 29 Jun 2023.
Clinical trials
- The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
45 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20255 payments$10,927openpaymentsdata.cms.gov ↗
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Janssen Research & Development, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.3%Thalidomide Analog46.3%Lenalidomide58%Revlimid42%Part D≥12 patientsDermatology
21.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.9%Acyclovir100%Part D≥12 patientsAnti-infectives
12.7%Short-acting sulfonamides7.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsTetracycline-class Drug5.7%Doxycycline Hyclate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Biology of Blood and Marrow Transplantation
2022 - Body composition from single versus multi‐slice abdominal computed tomography: Concordance and associations with colorectal cancer survival
Journal of Cachexia Sarcopenia and Muscle
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”